TOKYO, May 20 (Pulse News Wire) – StemCell Institute (7096.T) resolved to issue stock options to its directors, executives, employees, and those of its subsidiaries at the board meeting held . The proposal will be put forward at the 27th regular shareholders' meeting scheduled for June 24, 2026.
Additionally, the resolution seeks approval for granting stock options as part of compensation for directors based on the Black-Scholes model valuation method. Under the plan, the number of stock options granted will be determined based on the number of employees and their positions within the company. The exercise price of each option will be calculated as the average closing price of the company's shares on the Tokyo Stock Exchange in the month preceding the grant date, adjusted by 1.05, rounded up to the nearest whole number. In case of adjustments due to share splits, mergers, or capital reductions, the exercise price will also be adjusted accordingly.
Furthermore, the company plans to primarily utilize its treasury shares for issuing new shares upon the exercise of stock options. The total number of shares available for issuance through exercised options will be capped at 176,400. For directors specifically, the cap stands at 176,400 shares per individual option holder. The total number of stock options to be issued is limited to 1,764 options, with 1,764 options reserved for directors.
🟡 Confidence: Standard AI-translated content.